PDS Biotechnology Announces Conference Call and Webcast for Fourth Quarter 2022 Financial Results
16 mars 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Participate at 33rd Annual Oppenheimer Healthcare Conference
07 mars 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces the Publication of PDS0301 Study Linking Induced Changes in Immune Responses with Clinical Outcomes in International Immunopharmacology Journal
01 mars 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., March 01, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Completes Successful Meeting with FDA for Triple Combination of PDS0101, PDS0301 and a Commercial Immune Checkpoint Inhibitor
27 févr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Preclinical Publication in Peer Reviewed Viruses Journal Showing Superior CD4 T Cell Induction by Infectimune™
16 févr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 16, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Publication of Preclinical Infectimune™ Based Vaccine Studies Demonstrating Effective Protection Against Viral Infection in Peer-Reviewed Journal, Viruses
08 févr. 2023 16h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 08, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Abstract Accepted for Presentation at ESMO Targeted Anticancer Therapies Congress
06 févr. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Feb. 06, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Participation in the Channelchek Takeaway Series
26 janv. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 26, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech to Participate at the B. Riley Securities 3rd Annual Oncology Conference
13 janv. 2023 08h00 HE
|
PDS Biotechnology Corporation
FLORHAM PARK, N.J., Jan. 13, 2023 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies...
PDS Biotech Announces Exclusive Global License Agreement for Investigational IL-12 Tumor-Targeted Cytokine from Merck KGaA, Darmstadt, Germany
03 janv. 2023 07h00 HE
|
PDS Biotechnology Corporation
PDS Biotech bolsters immuno-oncology portfolio with a clinical-stage product synergistic with its Versamune® platform PDS Biotech to host conference call and webcast on Tuesday, January 3, 2023, at...